BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025

Core Insights - BridgeBio Pharma, Inc. announced the presentation of new data on its drug Acoramidis at the European Society of Cardiology (ESC) Congress 2025, highlighting its focus on genetic diseases [1] Presentation Details - A rapid-fire oral presentation will discuss the reduction in cardiovascular mortality (CVM) at Month 42 from the ATTRibute-CM open-label extension study, presented by Dr. Kevin Alexander on August 30 [2] - Two ePosters will be presented: one on the improvement in NT-proBNP at Month 30 compared to placebo, presented by Dr. Nitasha Sarswat on August 31, and another on the beneficial effect of Acoramidis on NAC ATTR stage at Month 30, presented by Dr. Julian Gillmore on August 29 [2][3] Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular death and related hospitalizations [3] Safety Information - Adverse reactions reported for Attruby included diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation [4]